Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET
Company Participants
Dr. William G. Rice – Chairman, President and Chief Executive Officer
Dr. Rafael Bejar – Senior Vice President and Chief Medical Officer
Dan Ferry – Managing Director, LifeSci Advisors LLC
Conference Call Participants
Gregory Renza – RBC Capital Markets
Matthew Biegler – Oppenheimer & Co. Inc.
Li Watsek – Cantor Fitzgerald
Matthew Cross – Allegiance Global Partners
Operator
Welcome to the Aptose Biosciences o Incorporated Reports Result for the First Quarter 2022 Conference Call. My name is Darryl and I will be your Operator for today's call. At this time, all participants are in listening-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to Dan Ferry. Dan, you may begin.
Dan Ferry
Thank you. Good afternoon and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the first quarter ended March 31st, 2022. Earlier today, Aptose issued a press release relating to these financial results. The news release, as well as related SCC filings are accessible on Aptose's website. Joining me on today's call are Dr. Dr. William G. Rice, Chairman, President and CEO and Dr. Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer.
Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of U.S. and Canadian securities laws. Forward-looking statements reflect Aptose's current expectations regarding future events, but are not guarantees of performance. It is possible that actual results and performance could differ materially from these stated expectations. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievement to differ materially from those expressed.
To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose's most recent annual report on Form 10-K and SCC and SEDAR filings. All forward-looking statements made during this call speak only as of the date they are made. Aptose undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law. I will now turn the call over to Dr. Rice, Chairman, President and CEO of Aptose Biosciences. Dr. Rice.
Dr. William G. Rice